Context Therapeutics announced third-quarter 2026 financial results and provided a positive pipeline update, highlighting longer-term follow-up data from its Phase 1 trial of CTIM-76. In heavily pretreated patients with platinum-resistant ovarian cancer (PROC), the drug demonstrated promising efficacy and a manageable safety profile.

Key Details

  • CTIM-76 Efficacy Data: Among efficacy-evaluable PROC patients (n=9) on weekly active doses, CTIM-76 showed a 22% confirmed objective response rate (ORR), a 56% disease control rate (DCR), and a median progression-free survival (PFS) of 5.6 months.
  • Upcoming Milestones: The company is advancing an every-three-week (Q3W) dosing schedule and expects to initiate a Phase 1b dose expansion study in Q1 2027. Initial efficacy data for the Q3W dosing is anticipated in Q2 2027.
  • Financial Position: As of September 30, 2026, the company reported cash and cash equivalents of $34.4 million, which is expected to fund operations into early Q4 2027.